Literature DB >> 21382289

Successful treatment of plasma cell cheilitis with topical tacrolimus: report of two cases.

Yuka Hanami1, Yoshikazu Motoki, Toshiyuki Yamamoto.   

Abstract

Plasma cell cheilitis is an uncommon chronic inflammatory dermatitis that presents with flat to slightly elevated erosive erythematous plaques. It is histologically characterized by plasma cell infiltrates into the mucosa. Other than the lip, genital areas are often involved, which is called plasma cell balanitis or vulvitis. Plasma cell cheilitis is sometimes resistant to conventional topical corticosteroid therapy. Other choices include oral griseofulvin, topical cyclosporine, and intralesional corticosteroid injection, all of which occasionally fail to produce satisfactory results. Recent reports show that topical calcineurin inhibitors are effective for plasma cell cheilitis, balanitis, and vulvitis. However, there are so far only 2 reports of plasma cell cheilitis successfully treated with topical pimecrolimus and tacrolimus. We present herein two cases of plasma cell cheilitis, in which topical tacrolimus showed beneficial effects, suggesting that this immunomodulatory agent is a promising option for plasma cell cheilitis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21382289

Source DB:  PubMed          Journal:  Dermatol Online J        ISSN: 1087-2108


  2 in total

1.  Plasma cell cheilitis: the diagnosis of a disorder mimicking lip cancer.

Authors:  Harim Tavares Dos Santos; John Lennon Silva Cunha; Lucas Alves Mota Santana; Cleverson Luciano Trento; Antônio Carlos Marquetti; Ricardo Luiz Cavalcanti de Albuquerque-Júnior; Sílvia Ferreira de Sousa
Journal:  Autops Case Rep       Date:  2019-03-22

2.  Plasma Cell Cheilitis: A Clinicopathological and Immunohistochemical Study of 13 Cases.

Authors:  Jin Yong Lee; Kwang Ho Kim; Ji Eun Hahm; Jae Won Ha; Won Joo Kwon; Chul Woo Kim; Sang Seok Kim
Journal:  Ann Dermatol       Date:  2017-08-25       Impact factor: 1.444

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.